Effect of norethindrone acetate in the treatment of symptomatic endometriosis.
article
OA: closed
CC0
⤵ 56 in-corpus citations
AI-generated summary
Norethindrone acetate relieved dysmenorrhea, noncyclic pelvic pain, and overall pain in most women with symptomatic endometriosis, despite breakthrough bleeding being a common side effect.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: The purpose of the study was to evaluate the efficacy of norethindrone acetate (NA) treatment in 52 women with dysmenorrhea, dyspareunia, noncyclic pelvic pain who had a diagnosis of endometriosis by laparoscopy. RESULTS: Dysmenorrhea and noncyclic pelvic pain were relieved in 48/52 (92.3%) and 25/28 (89.2%) of patients, respectively. Overall pain relief was obtained in 49/52 (94.2%) of patients. Breakthrough bleeding, of variable severity, was the most common side effect experienced by 30 patients (57.6%); however, only 4 patients (7.7%) dropped out for this side effect. One other patient dropped out for severe breast tenderness, and three for noncyclic pelvic pain. In general, treatment was successful in 44/52 (84.5%) of patients with the above symptoms. CONCLUSION: NA seems to be a cost-effective alternative with relatively mild side effects in the treatment of symptomatic endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (50)
- Optimize your treatment of endometriosis by using an FDA-approved hormonal medication 2021
- Medical management of endometriosis 2021
- Medical Treatment for Endometriosis: Tolerability, Quality of Life and Adherence 2021
- Endometriosis Treatment 2020
- Endometriosis 2019
- Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis? 2019
- Chapitre 3 : Prise en charge médicale de la douleur associée à l'endométriose 2019
- Future Directions in Endometriosis Research and Therapeutics 2018
- Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique®) in the treatment of endometriosis symptoms: A prospective open-label comparative study 2018
- Shifting from Oral Contraceptives to Norethisterone Acetate, or Vice Versa, because of Drug Intolerance: Does the Change Benefit Women with Endometriosis? 2018
- Medical treatment of endometriosis-related pain 2018
- Is Shifting to a Progestin Worthwhile When Estrogen—Progestins Are Inefficacious for Endometriosis-Associated Pain? 2018
- A stepped-care approach to symptomatic endometriosis management: a participatory research initiative 2018
- Oral and depot progestin therapy for endometriosis: towards a personalized medicine 2017
- Efficacy of Norethisterone in Patients with Ovarian Endometrioma 2017
- Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills 2017
- Women with inherited bleeding disorders and their offspring - the unresolved issues 2017
- Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis 2017
- Hormonal therapy for endometriosis: from molecular research to bedside 2016
- Progestin suppressed inflammation and cell viability of tumor necrosis factor‐α‐stimulated endometriotic stromal cells 2016
- Pharmacologic treatment of the ovarian endometrioma 2016
- Progestogens and Endometriosis 2015
- Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study 2015
- Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age 2014
- New trends of progestins treatment of endometriosis 2014
- Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment 2014
- Medical Treatments for Endometriosis-Associated Pelvic Pain 2014
- Medikamentöse Therapie der Endometriose 2013
- Surgical versus low-dose progestin treatment for endometriosis-associated severe deep dyspareunia II: Effect on sexual functioning, psychological status and health-related quality of life 2013
- Norethindrone Acetate in the Medical Management of Adenomyosis 2012
- Medical management of recurrent endometrioma with long-term norethindrone acetate 2012
- Management of Chronic Pelvic Pain 2011
- Use of Norethindrone Acetate Alone for Postoperative Suppression of Endometriosis Symptoms 2011
- Brief update on endometriosis treatment 2011
- Medical Therapies: Progestins 2011
- Innovations in conservative endometriosis treatment: an updated review. 2011
- Endometrioza w wieku przed- i oko³omenopauzalnym - jak leczyæ? Endometriosis in pre- and perimenopausal age - how to treat? 2011
- Endometriosis in pre- and perimenopausal age – how to treat? 2011
- Dienogest in long-term treatment of endometriosis 2011
- Current pharmacotherapy for endometriosis 2010
- Medical Management of Pain Associated With Endometriosis 2010
- Dienogest: an oral progestogen for the treatment of endometriosis 2010
- Aspectos atuais do diagnóstico e tratamento da endometriose 2010
- Membranous Dysmenorrhea 2010
- Endometriosis 2009
- Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study 2009
- Noninvasive assessment of ectopic uterine tissue development in rats using magnetic resonance imaging 2007
- The role of progestins in treating the pain of endometriosis 2006
- Medical Management of Endometriosis 2006
- Tratamento da endometriose 2006
Source provenance
- europepmc
- last seen: 2026-06-13T06:22:48.782012+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:10:40.754221+00:00
License: CC0
· commercial use OK